1. Home
  2. SBFG vs ADCT Comparison

SBFG vs ADCT Comparison

Compare SBFG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$26.88

Market Cap

164.8M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.27

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
ADCT
Founded
1983
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.8M
136.1M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
SBFG
ADCT
Price
$26.88
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
62.8K
1.5M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
2.98%
N/A
EPS Growth
27.33
30.86
EPS
0.69
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
$39.07
N/A
Revenue Growth
N/A
14.85
52 Week Low
$18.16
$0.78
52 Week High
$27.69
$4.98

Technical Indicators

Market Signals
Indicator
SBFG
ADCT
Relative Strength Index (RSI) 67.71 40.09
Support Level $20.94 $0.78
Resistance Level N/A $1.44
Average True Range (ATR) 0.99 0.11
MACD 0.09 0.08
Stochastic Oscillator 85.11 60.67

Price Performance

Historical Comparison
SBFG
ADCT

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: